Gianfranco Dedivitiis

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Non-Surgical Management of Methicillin-Sensitive Staphylococcus Aureus Bacteremia-Related Mediastinitis.

Non-Surgical Management of Methicillin-Sensitive Staphylococcus Aureus Bacteremia-Related Mediastinitis.

Journal: European journal of case reports in internal medicine

Published: September 17, 2024

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.

Journal: Virology journal

Published: September 07, 2023

Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects.

Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects.

Journal: Human vaccines & immunotherapeutics

Published: May 05, 2022

Persistence of Long-COVID symptoms in a heterogenous prospective cohort.

Persistence of Long-COVID symptoms in a heterogenous prospective cohort.

Journal: The Journal of infection

Published: January 16, 2022

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG.

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG.

Journal: The Journal of infection

Published: May 20, 2021

Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.

Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 11, 2021

Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study.

Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study.

Journal: The Journal of infection

Published: January 24, 2021

Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal carriers.

Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal carriers.

Journal: Journal of medical virology

Published: August 01, 2020

Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study.

Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study.

Journal: Medicine

Published: February 17, 2017

Showing 1-9 of 9

Last Updated: 09/26/2026